The biopharmaceutical company in Exton formerly known as Aqua Pharmaceuticals is getting ready to enter the new year with a new name and an expanded roster of dermatology products, writes John George for the Philadelphia Business Journal.

The company changed its name to Almirall in October, after a major acquisition by its parent company.

Starting in 2019, the company’s portfolio will include Seysara. The acne treatment was still under review by the Food and Drug Administration when it was bought by Almirall’s parent company, Almirall SA.

The company acquired Seysara, along with four already approved products from Allergan, in September for $550 million. Two weeks after the sale was announced, the FDA approved Seysara for use in treating inflammatory lesions in patients with moderate to severe acne.

“It happened way before we expected,” said Ron Menezes, the president of Almirall. “I think the reason is the FDA is really encouraging the development of new antibiotics.”

The company has already increased its staff from around 80 to 110 people.

Read more about Almirall in the Philadelphia Business Journal here.

[uam_ad id=”80503″]

.

[uam_ad id=”80502″]